COSENTYX

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug COSENTYX contains one active pharmaceutical ingredient (API):

1	Secukinumab UNII DLG4EML025 - SECUKINUMAB
	Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases.
	Read more about Secukinumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
COSENTYX Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC10	Secukinumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10425Q, 10494H, 10890E, 10893H, 10894J, 10895K, 10898N, 10899P, 10900Q, 10901R, 10906B, 10910F, 12297F, 12307R, 12321L
BR	Câmara de Regulação do Mercado de Medicamentos	526516050085902, 526516050086002, 526516050086102, 526516050086202, 526516050086302, 526521060098603
CA	Health Products and Food Branch	02438070
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	30-MBE-1015, 34-MBE-1115
EE	Ravimiamet	1675616, 1675627, 1675638, 1675649, 1675650, 1704912, 1704923, 1833948, 1833959, 1833960, 1833982, 1857034, 1857045
ES	Centro de información online de medicamentos de la AEMPS	114980003, 114980004, 114980005, 114980010
FI	Lääkealan turvallisuus- ja kehittämiskeskus	156439, 445576, 478929, 555196
FR	Base de données publique des médicaments	63549069, 65007804
GB	Medicines & Healthcare Products Regulatory Agency	292126, 348713, 393239
HK	Department of Health Drug Office	64235, 64237, 64238, 67151, 67152
IE	Health Products Regulatory Authority	88096, 88172, 89092
IL	מִשְׂרַד הַבְּרִיאוּת	7754, 7755, 9322, 9323
JP	医薬品医療機器総合機構	3999439G2028, 3999439G3024, 3999439G4020
LT	Valstybinė vaistų kontrolės tarnyba	1075453, 1075454, 1075455, 1075456, 1075457, 1076650, 1076651, 1091485, 1091486, 1091487, 1091488, 1092976, 1092977
NL	Z-Index G-Standaard, PRK	124397, 124400
NZ	Medicines and Medical Devices Safety Authority	17618, 17619
PL	Rejestru Produktów Leczniczych	100333193, 100333224, 100444946, 100467410
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64460001, W64460002, W67058001, W67211001, W67964001
SG	Health Sciences Authority	14749P, 14750P, 14751P
TN	Direction de la Pharmacie et du Médicament	12433111H, 12433112H
US	FDA, National Drug Code	0078-0639
ZA	Health Products Regulatory Authority	49/30.1/0232, 49/30.1/0233